Tetra Bio-Pharma Inc. (TBP.TO)
Chart Events
Performance Outlook
| Previous Close | 0.0350 |
| Open | 0.0400 |
| Bid | 0.0350 x N/A |
| Ask | 0.0400 x N/A |
| Day's Range | 0.0400 - 0.0400 |
| 52 Week Range | 0.0300 - 0.2650 |
| Volume | |
| Avg. Volume | 339,595 |
| Market Cap | 16.935M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | Jul 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TBP.TO
Related Research
- CNW Group
Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the "Financing") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean ("ABO"), and has closed the first tranche of the Financing on such revised terms, the whole pursuant to the term
- PR Newswire
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC ("Cellvera"), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.
